Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) Non Operating Income: 2021-2025

Historic Non Operating Income for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Sep 2025 value amounting to $2.0 million.

  • Arcutis Biotherapeutics' Non Operating Income fell 51.34% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.6 million, marking a year-over-year decrease of 40.60%. This contributed to the annual value of $16.2 million for FY2024, which is 37.22% up from last year.
  • As of Q3 2025, Arcutis Biotherapeutics' Non Operating Income stood at $2.0 million, which was down 2.91% from $2.1 million recorded in Q2 2025.
  • Over the past 5 years, Arcutis Biotherapeutics' Non Operating Income peaked at $5.2 million during Q2 2024, and registered a low of -$1.7 million during Q1 2022.
  • For the 3-year period, Arcutis Biotherapeutics' Non Operating Income averaged around $3.2 million, with its median value being $2.7 million (2025).
  • Data for Arcutis Biotherapeutics' Non Operating Income shows a peak YoY increase of 8,400.00% (in 2022) and a maximum YoY decrease of 4,044.19% (in 2022) over the last 5 years.
  • Arcutis Biotherapeutics' Non Operating Income (Quarterly) stood at -$40,000 in 2021, then soared by 8,400.00% to $3.3 million in 2022, then fell by 19.52% to $2.7 million in 2023, then grew by 1.72% to $2.7 million in 2024, then plummeted by 51.34% to $2.0 million in 2025.
  • Its Non Operating Income was $2.0 million in Q3 2025, compared to $2.1 million in Q2 2025 and $2.7 million in Q1 2025.